JPH0511091B2 - - Google Patents
Info
- Publication number
- JPH0511091B2 JPH0511091B2 JP60032330A JP3233085A JPH0511091B2 JP H0511091 B2 JPH0511091 B2 JP H0511091B2 JP 60032330 A JP60032330 A JP 60032330A JP 3233085 A JP3233085 A JP 3233085A JP H0511091 B2 JPH0511091 B2 JP H0511091B2
- Authority
- JP
- Japan
- Prior art keywords
- pva
- concentration
- gel
- aqueous solution
- degree
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 86
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 86
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 21
- 239000003405 delayed action preparation Substances 0.000 claims description 15
- 230000008014 freezing Effects 0.000 claims description 15
- 238000007710 freezing Methods 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 10
- 239000000499 gel Substances 0.000 description 55
- 239000000017 hydrogel Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 206010042674 Swelling Diseases 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 13
- 239000012071 phase Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000013268 sustained release Methods 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- 238000006116 polymerization reaction Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000007127 saponification reaction Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3233085A JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3233085A JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61191609A JPS61191609A (ja) | 1986-08-26 |
| JPH0511091B2 true JPH0511091B2 (pt) | 1993-02-12 |
Family
ID=12355928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3233085A Granted JPS61191609A (ja) | 1985-02-20 | 1985-02-20 | 徐放性製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61191609A (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0516026A1 (en) * | 1991-05-28 | 1992-12-02 | Takeda Chemical Industries, Ltd. | Hydrogel and method of producing same |
| DE19751031A1 (de) | 1997-11-19 | 1999-06-24 | Ingo Dipl Ing Heschel | Verfahren zur Herstellung poröser Strukturen |
| US20070218139A1 (en) * | 2002-12-20 | 2007-09-20 | Smith Thomas J | High Pressure Compaction For Pharmaceutical Formulations |
| US20230148062A1 (en) * | 2020-04-10 | 2023-05-11 | Japan Vam & Poval Co., Ltd. | Binder |
| CN111606630B (zh) * | 2020-06-15 | 2021-12-17 | 陕西金磊混凝土有限公司 | 免蒸养高流动性混凝土及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956446A (ja) * | 1982-09-24 | 1984-03-31 | Nippon Oil Co Ltd | ポリビニルアルコ−ル凍結ゲルの柔軟性低下法 |
-
1985
- 1985-02-20 JP JP3233085A patent/JPS61191609A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5956446A (ja) * | 1982-09-24 | 1984-03-31 | Nippon Oil Co Ltd | ポリビニルアルコ−ル凍結ゲルの柔軟性低下法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61191609A (ja) | 1986-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4591496A (en) | Process for making systems for the controlled release of macromolecules | |
| US5540912A (en) | Viscous suspensions of controlled-release drug particles | |
| US5759583A (en) | Sustained release poly (lactic/glycolic) matrices | |
| US4164560A (en) | Systems for the controlled release of macromolecules | |
| US4391797A (en) | Systems for the controlled release of macromolecules | |
| RU2093148C1 (ru) | Композиции с замедленным (пролонгированным) высвобождением | |
| US5346935A (en) | Hydrogel | |
| US6488952B1 (en) | Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system | |
| US5081156A (en) | Sustained-release preparation | |
| EP1592405B1 (en) | Composition for chemoembolotherapy of solid tumors | |
| JPH09510468A (ja) | 皮膚疾患の治療のための及びその皮膚の消毒のためのゲル | |
| CN108126237B (zh) | 一种磺胺嘧啶银温敏凝胶及其制备方法和应用 | |
| JP2012162561A (ja) | キセロゲルまたはフィルムの形態での局所使用のための医薬組成物および製造方法 | |
| CN106456563A (zh) | 释放一氧化氮的伤口处理膜及其制备方法 | |
| JPH04295418A (ja) | 成分放出が制御された合成物 | |
| Krajacic et al. | Matrix formation in sustained release tablets: possible mechanism of dose dumping | |
| JPH0511091B2 (pt) | ||
| US4781926A (en) | Transdermal therapeutic composition | |
| JPH01230659A (ja) | 粘着性ｐｖａハイドロゲル組成物 | |
| Shi et al. | Sustained release of alginate hydrogel containing antimicrobial peptide Chol-37 (F34-R) in vitro and its effect on wound healing in murine model of Pseudomonas aeruginosa infection | |
| CN106491517B (zh) | 吡非尼酮pva水凝胶的制备方法及吡非尼酮pva水凝胶 | |
| AU661726B2 (en) | Peroral drug delivery system | |
| SK1795A3 (en) | Drug delivery device and method of this production | |
| JPH01186823A (ja) | 薬物透過性物質の製造方法 | |
| RU2201219C2 (ru) | Фармакологическая композиция пролонгированного действия |